MASH

Metabolic Health

Tirzepatide for MASH: Phase 2 Signals Reshape the Liver-Metabolic Playbook

A dual GIP/GLP-1 agonist already changing diabetes and obesity care is now posting credible early signals against the fatty-liver disease that often travels with them.

Peptides

The New GLP-1 Frontier: Combo Stacks, Cardio Synergy, and the Oral Pill Race

GLP-1s aren't just a shred-cycle headline anymore. The next wave — liver-targeting combos, cardiovascular synergy with training, and oral delivery — is rewriting what these peptides can do.